J&J earnings rise on strong consumer, pharma sales

Share this article:

Johnson & Johnson said its overall earnings increased 9.5% fueled by strong sales from its consumer products division and rising pharmaceutical sales.

J&J pharmaceutical sales were up 7.5% fueled by antipsychotic medication Risperdal, the drugmaker said Tuesday. Meanwhile J&J's consumer-product division saw sales rise 49% backed by a strong performance from Listerine antiseptic mouthwash, the launch of teeth-whitening products and Splenda sweetener among other products.

Johnson & Johnson announced it would purchase Pfizer's consumer healthcare business for $16.6 billion in June 2006, adding brands such as Listerine, Lubriderm, Visine, Neosporin, Sudafed, Zantac and Benadryl to its already lucrative consumer division.

“Consumer is the driving force for J&J, and will be through at least this year,'' said Bruce Cranna, an analyst with Leerink Swann & Co. in an interview with Bloomberg.com.

Johnson & Johnson sales data
(Sales to customers by segment of business)

                                      
                                          2007            2006

Pharmaceutical
US                                   $15,603       $15,092
International                      $9,263         $8,175

Consumer
US                                     $6,408        $4,573
International                      $8,085        $5,201
      
                                            -data provided by Johnson & Johnson

Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union